+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Childhood Absence Epilepsy Treatment Market by Treatment Type (Anti-Seizure Medication, Dietary Therapy, Neurostimulation), Drug Class (Ethosuximide, Lamotrigine, Levetiracetam), End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Childhood Absence Epilepsy Treatment Market by Treatment Type (Anti-Seizure Medication, Dietary Therapy, Neurostimulation), Drug Class (Ethosuximide, Lamotrigine, Levetiracetam), End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Childhood Absence Epilepsy Treatment Market by Treatment Type (Anti-Seizure Medication, Dietary Therapy, Neurostimulation), Drug Class (Ethosuximide, Lamotrigine, Levetiracetam), End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010834
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Childhood Absence Epilepsy Treatment Market grew from USD 255.22 million in 2024 to USD 274.62 million in 2025. It is expected to continue growing at a CAGR of 7.46%, reaching USD 393.11 million by 2030.

A Comprehensive Overview of Childhood Absence Epilepsy Treatment Landscape Highlighting Current Challenges Emerging Strategies and Clinical Perspectives to Enhance Patient Outcomes

Childhood absence epilepsy represents a unique neurological condition characterized by brief, sudden lapses in consciousness that can disrupt cognitive development, social interaction, and daily learning experiences for young patients. These transient but recurrent seizures demand a nuanced therapeutic approach that balances efficacy, tolerability, and long-term safety. As the incidence of absence epilepsy continues to command the attention of pediatric neurologists and caregivers alike, the landscape of available treatments has expanded beyond traditional pharmacotherapies to include dietary interventions and advanced neurostimulation techniques.

Against this backdrop, the imperative for a comprehensive examination of emerging treatment modalities has never been greater. This executive summary synthesizes multidisciplinary perspectives spanning clinical practice, regulatory developments, and technological innovation. By highlighting pivotal advances and contextual challenges, readers will gain a holistic understanding of how treatment paradigms are evolving to meet the needs of diverse patient populations. The insights contained herein serve as a foundation for informed decision making by healthcare providers, pharmaceutical developers, device manufacturers, and policy makers dedicated to improving outcomes for children affected by absence epilepsy.

Transformational Advances Reshaping Childhood Absence Epilepsy Management Driven by Novel Therapies Technological Innovations and Evolving Clinical Protocols

Over the past decade, the management of childhood absence epilepsy has undergone a significant transformation driven by advances in pharmacology, personalized care models, and technological innovation. Newly refined anti-seizure medications have emerged with enhanced specificity and reduced side effect profiles, while the implementation of precision dosing strategies has begun to reshape standard clinical protocols. These shifts have been fueled by improved understanding of genetic predispositions and seizure network dynamics, allowing clinicians to tailor interventions more effectively.

Simultaneously, non-pharmacological approaches have gained traction. Dietary regimens adapted to low-carbohydrate, high-fat constituents offer a complementary pathway for seizure control, showcasing the potential for metabolic modulation as a viable treatment adjunct. Additionally, breakthroughs in neurostimulation-where targeted electrical impulses modulate aberrant neural circuitry-have created new opportunities for refractory cases. As research continues to validate the safety and efficacy of these therapies, their integration into multidisciplinary treatment frameworks underscores a broader move toward patient-centric, evidence-based care.

Assessing the Broad Implications of United States 2025 Tariff Adjustments on Childhood Absence Epilepsy Treatment Supply Chains Pricing and Patient Access

In 2025, the introduction of revised United States tariffs on imported pharmaceuticals and medical devices has reverberated through the childhood absence epilepsy treatment ecosystem. Increased duties on key anti-seizure medication active ingredients have compelled manufacturers to reassess sourcing strategies and negotiate alternative supply channels. Consequently, some regional production sites have accelerated local manufacturing initiatives to mitigate tariff-induced cost pressures, while others have pursued strategic alliances to ensure continuity of critical drug supplies.

Moreover, devices integral to neurostimulation therapies-ranging from vagus nerve stimulators to deep brain stimulator components-have encountered extended lead times and elevated import costs. In response, device developers are exploring modular manufacturing and in-country assembly programs to preserve affordability for healthcare providers. These dynamics have shaped reimbursement negotiations and may influence patient access frameworks in the near term. As stakeholders adapt to the evolving regulatory environment, agility in supply chain management and proactive engagement with policy makers will be crucial to sustaining treatment availability and maintaining therapeutic innovation.

In-Depth Segmented Analysis Revealing Treatment Type Drug Class End User and Distribution Channel Dynamics Influencing Childhood Absence Epilepsy Therapeutics

Segmented analysis of the childhood absence epilepsy treatment landscape reveals critical insights across multiple dimensions. In terms of treatment modalities, the therapeutic portfolio encompasses anti-seizure medication therapies such as ethosuximide, lamotrigine, levetiracetam, and valproate alongside dietary interventions exemplified by the classical ketogenic diet and its modified Atkins counterpart, and advanced neurostimulation approaches including vagus nerve stimulation and deep brain stimulation. When dissected by drug class, outcomes associated with each medication underscore variations in efficacy and tolerability that inform both prescribing patterns and patient adherence trends.

Further granularity emerges when considering the end user environments that deliver these therapies. Caregiver-managed and home nursing scenarios reflect growing interest in decentralized care models, while inpatient and outpatient hospital settings continue to serve as hubs for acute management and treatment initiation. Additionally, specialized centers-epilepsy monitoring units and pediatric neurology clinics-offer advanced diagnostic capabilities and tailored therapeutic regimens. Distribution pathways extend from hospital pharmacies through online dispensing channels to retail pharmacy networks, each with distinct reimbursement structures and accessibility implications. Together, these intersecting segments shape a complex ecosystem in which stakeholders must navigate clinical, logistical, and economic factors to optimize patient outcomes.

Critical Regional Perspectives Highlighting Distinctive Growth Drivers Challenges and Opportunities in the Americas Europe Middle East Africa and Asia-Pacific Markets

Regional perspectives on childhood absence epilepsy treatment underscore pronounced variations in healthcare infrastructure, reimbursement policies, and therapeutic adoption rates. In the Americas, robust research initiatives and established pediatric neurology networks support rapid integration of novel pharmacological agents, while home care delivery models have expanded to include telehealth-enabled nursing and caregiver training programs. These developments are underpinned by concerted efforts to streamline supply chain logistics and ensure equitable patient access across both urban centers and remote communities.

Conversely, markets within Europe, the Middle East, and Africa exhibit heterogeneous regulatory landscapes that influence the pace of therapeutic innovation and pricing strategies. Collaborative procurement frameworks and regional pharmaceutical alliances have emerged as key mechanisms to negotiate favorable drug and device tariffs, enhancing availability of both traditional anti-seizure medications and neurostimulation solutions. Meanwhile, Asia-Pacific markets demonstrate accelerating uptake of dietary therapies, particularly modified ketogenic protocols, supported by growing clinical expertise and local dietary customization initiatives. These regional nuances highlight the importance of tailored market entry strategies and adaptive engagement with local clinical ecosystems.

Strategic Company Profiles and Competitive Insights Spotlighting Leading Pharmaceutical Device and Dietary Therapy Providers in Childhood Absence Epilepsy

The competitive landscape for childhood absence epilepsy treatment is characterized by a diverse array of pharmaceutical companies, device manufacturers, and specialized nutrition providers. Leading anti-seizure medication developers have focused on pipeline optimization and strategic licensing agreements to expand their pediatric neurology portfolios. Concurrently, neurostimulation device innovators are investing in next-generation platforms that emphasize patient comfort, remote programming capabilities, and extended battery life.

In the dietary therapy segment, niche providers of medical nutrition have forged partnerships with academic institutions to validate regimen efficacy and refine patient adherence models. Collaborative ventures between pharmaceutical and device companies are also gaining momentum, with cross-disciplinary teams working to integrate pharmacotherapy protocols with neuromodulation adjuncts. As market entrants vie for leadership, differentiation hinges on demonstrating clinical value, securing favorable reimbursement coverage, and building robust real-world evidence through post-market surveillance studies.

Pragmatic and Forward-Looking Recommendations for Industry Leaders to Navigate Regulatory Complexities Innovate Therapeutic Solutions and Optimize Market Penetration

Industry leaders can capitalize on emerging opportunities by adopting a multifaceted strategic framework. First, diversifying supply chains through dual sourcing arrangements and localized manufacturing hubs will mitigate exposure to tariff fluctuations and geopolitical disruptions. Coupled with proactive engagement in policy advocacy, these measures will support uninterrupted delivery of essential therapies.

Second, investing in comprehensive patient support programs-ranging from digital health platforms for seizure monitoring to caregiver education initiatives-will enhance treatment adherence and improve long-term outcomes. Partnerships with specialty clinics and telehealth providers can extend these resources across geographically dispersed patient populations. Finally, fostering collaborative research endeavors that integrate pharmacological and neuromodulation modalities will not only accelerate product development but also position organizations as thought leaders within the pediatric epilepsy community.

Robust and Transparent Research Methodology Combining Primary Interviews Secondary Data Sources and Advanced Analytical Techniques to Ensure Credibility

This research employs a rigorous and transparent methodology designed to deliver robust, evidence-based insights. Primary data collection involved in-depth interviews with leading pediatric neurologists, dietitians, medical device engineers, and patient advocacy representatives to capture firsthand perspectives on treatment efficacy, safety considerations, and care delivery challenges. These qualitative inputs were complemented by secondary analyses of peer-reviewed clinical studies, regulatory filings, treatment protocols, and real-world evidence from health technology registries.

Analytical techniques included cross-segmentation correlation assessments and scenario-based supply chain risk modeling to elucidate the interplay between therapeutic modalities, distribution channels, and regional market dynamics. Continuous validation checkpoints, involving expert advisory panels and data triangulation exercises, ensured the integrity and reliability of our findings. This comprehensive approach allows stakeholders to make informed strategic decisions grounded in empirical evidence and aligned with evolving clinical and regulatory imperatives.

Conclusive Reflections on the Evolution of Childhood Absence Epilepsy Treatment Strategies Key Learnings and Future Outlook for Stakeholders

The evolving landscape of childhood absence epilepsy treatment underscores the significance of integrating multifaceted therapeutic approaches to address the unique needs of pediatric patients. Innovations in anti-seizure medications, dietary interventions, and neurostimulation have collectively expanded the arsenal available to clinicians, enabling more personalized treatment trajectories that balance efficacy with quality-of-life considerations.

Looking ahead, continued collaboration among pharmaceutical innovators, device manufacturers, nutrition specialists, and healthcare providers will be essential to overcome remaining challenges related to access, affordability, and long-term safety monitoring. By leveraging comprehensive data analytics and real-world evidence, stakeholders can refine treatment guidelines and enhance patient support mechanisms. This confluence of scientific advancement and strategic partnership will ultimately catalyze improved outcomes and foster a new era of optimized care for children living with absence epilepsy.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Anti-Seizure Medication
      • Ethosuximide
      • Lamotrigine
      • Levetiracetam
      • Valproate
    • Dietary Therapy
      • Ketogenic Diet
      • Modified Atkinson Regimen
    • Neurostimulation
      • Deep Brain Stimulation
      • Vagus Nerve Stimulation
  • Drug Class
    • Ethosuximide
    • Lamotrigine
    • Levetiracetam
    • Valproate
  • End User
    • Home Care Settings
      • Caregiver Managed
      • Home Nursing
    • Hospitals
      • Inpatient
      • Outpatient
    • Specialty Clinics
      • Epilepsy Monitoring Units
      • Pediatric Neurology Centers
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • UCB S.A.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of precision medicine approaches integrating genomic profiling in childhood absence epilepsy treatment
5.2. Development of long-acting antiepileptic drug formulations targeting improved compliance in pediatric patients
5.3. Adoption of real-world evidence studies to evaluate comparative efficacy and safety of absence epilepsy therapies
5.4. Integration of AI-powered EEG pattern recognition tools for early diagnosis and treatment optimization
5.5. Emergence of novel GABA receptor modulators addressing drug resistance in childhood absence epilepsy management
5.6. Increasing investment in pediatric neurology clinical trials focusing on cannabidiol and other cannabinoid derivatives
5.7. Growing collaboration between biotech firms and academic centers for pediatric absence epilepsy drug discovery
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Childhood Absence Epilepsy Treatment Market, by Treatment Type
8.1. Introduction
8.2. Anti-Seizure Medication
8.2.1. Ethosuximide
8.2.2. Lamotrigine
8.2.3. Levetiracetam
8.2.4. Valproate
8.3. Dietary Therapy
8.3.1. Ketogenic Diet
8.3.2. Modified Atkinson Regimen
8.4. Neurostimulation
8.4.1. Deep Brain Stimulation
8.4.2. Vagus Nerve Stimulation
9. Childhood Absence Epilepsy Treatment Market, by Drug Class
9.1. Introduction
9.2. Ethosuximide
9.3. Lamotrigine
9.4. Levetiracetam
9.5. Valproate
10. Childhood Absence Epilepsy Treatment Market, by End User
10.1. Introduction
10.2. Home Care Settings
10.2.1. Caregiver Managed
10.2.2. Home Nursing
10.3. Hospitals
10.3.1. Inpatient
10.3.2. Outpatient
10.4. Specialty Clinics
10.4.1. Epilepsy Monitoring Units
10.4.2. Pediatric Neurology Centers
11. Childhood Absence Epilepsy Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Americas Childhood Absence Epilepsy Treatment Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Childhood Absence Epilepsy Treatment Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Childhood Absence Epilepsy Treatment Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. GlaxoSmithKline plc
15.3.3. UCB S.A.
15.3.4. Sanofi S.A.
15.3.5. Sun Pharmaceutical Industries Ltd.
15.3.6. Teva Pharmaceutical Industries Ltd.
15.3.7. Viatris Inc.
15.3.8. Pfizer Inc.
15.3.9. Johnson & Johnson
15.3.10. Novartis AG
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: RESEARCHAI
FIGURE 24. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 25. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 26. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY KETOGENIC DIET, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY KETOGENIC DIET, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY MODIFIED ATKINSON REGIMEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY MODIFIED ATKINSON REGIMEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DEEP BRAIN STIMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VAGUS NERVE STIMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ETHOSUXIMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY VALPROATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY CAREGIVER MANAGED, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY CAREGIVER MANAGED, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME NURSING, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME NURSING, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY EPILEPSY MONITORING UNITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY EPILEPSY MONITORING UNITS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PEDIATRIC NEUROLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY PEDIATRIC NEUROLOGY CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 127. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 128. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 129. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
TABLE 130. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2030 (USD MILLION)
TABLE 131. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
TABLE 132. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2030 (USD MILLION)
TABLE 133. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
TABLE 134. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2030 (USD MILLION)
TABLE 135. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 136. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 137. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 140. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 141. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 142. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 143. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 144. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 145. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. CANADA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 148. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 149. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
TABLE 150. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2030 (USD MILLION)
TABLE 151. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
TABLE 152. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2030 (USD MILLION)
TABLE 153. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
TABLE 154. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2030 (USD MILLION)
TABLE 155. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 156. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 157. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 160. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 161. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 162. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 163. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 164. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 165. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. MEXICO CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 250. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 251. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
TABLE 252. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2030 (USD MILLION)
TABLE 253. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
TABLE 254. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2030 (USD MILLION)
TABLE 255. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
TABLE 256. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2030 (USD MILLION)
TABLE 257. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 258. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 259. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 262. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2025-2030 (USD MILLION)
TABLE 263. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 264. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 265. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
TABLE 266. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, 2025-2030 (USD MILLION)
TABLE 267. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. GERMANY CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 270. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 271. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2018-2024 (USD MILLION)
TABLE 272. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY ANTI-SEIZURE MEDICATION, 2025-2030 (USD MILLION)
TABLE 273. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2018-2024 (USD MILLION)
TABLE 274. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DIETARY THERAPY, 2025-2030 (USD MILLION)
TABLE 275. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2018-2024 (USD MILLION)
TABLE 276. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY NEUROSTIMULATION, 2025-2030 (USD MILLION)
TABLE 277. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 278. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 279. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, 2018-2024 (USD MILLION)
TABLE 282. FRANCE CHILDHOOD ABSENCE EPILEPSY TREATMENT MARKET SI

Samples

Loading
LOADING...

Companies Mentioned

  • AbbVie Inc.
  • GlaxoSmithKline plc
  • UCB S.A.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 274.62 Million
Forecasted Market Value ( USD ) by 2030 $ 393.11 Million
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Lennox Gastaut Syndrome Global Market Report 2025 - Product Image

Lennox Gastaut Syndrome Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Lennox Gastaut Syndrome Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035 - Product Image

Lennox Gastaut Syndrome Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Anti-Epileptic Drugs for Pediatrics - Global Strategic Business Report - Product Image

Anti-Epileptic Drugs for Pediatrics - Global Strategic Business Report

  • Report
  • 367 Pages
  • Global
From
Partial Epilepsy Epidemiology Forecast 2025-2034 - Product Image

Partial Epilepsy Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
Anticonvulsants Market by Drug Class (Benzodiazepines, Carbonic Anhydrase Inhibitors, Gaba Analogues), Indication (Bipolar Disorder, Epilepsy, Migraine Prophylaxis), Route Of Administration, Distribution Channel - Global Forecast 2025-2030 - Product Image

Anticonvulsants Market by Drug Class (Benzodiazepines, Carbonic Anhydrase Inhibitors, Gaba Analogues), Indication (Bipolar Disorder, Epilepsy, Migraine Prophylaxis), Route Of Administration, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.